Acute topiramate differentially affects human aggressive responding at low vs.  moderate doses in subjects with histories of substance abuse and antisocial behavior.
Anticonvulsant drugs have demonstrated efficacy in the management of irritability and aggression in a variety of psychiatric populations. We examined the acute effects of topiramate on aggression using a laboratory model of human aggression (PSAP) in individuals at high risk for aggressive and violent behavior.Twelve subjects, on parole/probation and with an Axis-II personality disorder and/or a substance use disorder, received 100, 200, 300, and 400 mg in an ascending sequence, with intervening placebo doses.Subjects participated 2-3 days per week over 4-6 weeks. Due to cognitive side effects at 300 mg, two subjects only completed through the 200 mg dose. Topiramate produced an inverted U-shaped dose response curve, with increases in aggression peaking at 200 mg and a modest decrease at 400 mg. Statistical analysis revealed a polynomial trend for dose (p=0.001). The observed inverted U-shaped function in aggressive responding is consistent with non-human aggression studies of GABA-A modulators. Acute topiramate doses >400 mg may have anti-aggressive effects, but dose levels in the 200-300 mg range may produce increases in aggression and side effects.
Lane
Scott D
SD
Department of Psychiatry & Behavioral Sciences, Graduate School of Biomedical Sciences, University of Texas Health Science Center-Houston, Houston, TX 77030, United States. scott.d.lane@uth.tmc.edu
Gowin
Joshua L
JL
Green
Charles E
CE
Steinberg
Joel L
JL
Moeller
F  Gerard
F
Cherek
Don R
DR
D000328:Adult; D000374:Aggression / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012919:Social Behavior; D019966:Substance-Related Disorders / Q000188:drug therapy*; D000077236:Topiramate
D000077236:Topiramate; D005632:Fructose